November 7, 2017 07:01 AM EST

Boasting in-license distribution model, Chinese EOC Pharma bags $32M series B funding for oncology products

Amber Tong

With a newly pocketed $32 million series B, EOC Pharma is looking to bring potential blockbuster oncology drugs to China — products that it will have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boasting in-license distribution model, Chinese EOC Pharma bags $32M series B funding for oncology products

Amber Tong

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Boast­ing in-li­cense dis­tri­b­u­tion mod­el, Chi­nese EOC Phar­ma bags $32M se­ries B fund­ing for on­col­o­gy prod­ucts

Amber Tong

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Boasting in-license distribution model, Chinese EOC Pharma bags $32M series B funding for oncology products

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US